Moreover, EGR1 upregulation has been linked to enhanced p53 activity and increased intracellular levels of p66, which may accelerate the progression of NAFLD to liver fibrosis (4, 5, 23–26). The gene discussed is EGR1; the disease is metabolic dysfunction-associated steatotic liver disease.